Understanding resistance to targeted therapies in head and neck, breast cancer
MSN highlights University of Cincinnati Cancer Center research
MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor (EGFR)-targeted therapies often fail in breast and head and neck cancers.
The review, led by co-corresponding authors Vinita Takiar, MD, and Susan Waltz, PhD, offers an in-depth look at the molecular barriers to EGFR inhibition and provides insights that could inform the development of more effective and durable treatments.
EGFR is a critical protein that regulates cell growth and survival, and it is frequently overexpressed in breast and head and neck cancers. Although therapies targeting EGFR showed early promise, resistance has become a significant challenge.
The review analyzes resistance mechanisms in breast cancer including the movement of EGFR from the cell surface into the nucleus, promoting DNA repair. By analyzing these resistance mechanisms, the authors highlight combination therapies from current research that target EGFR and other key molecular pathways that may enhance treatment outcomes.
"A recent phase 1 study has shown that patients with recurrent or metastatic head and neck cancer who received BCA101, a bifunctional dual targeting drug that targets EGFR and TGF-β in combination with pembrolizumab, were able to achieve an overall response rate of 65%," the coauthors noted.
Featured photo at top of pink Breast Cancer Awareness ribbon. Photo/Lludmila Chernetska/iStock.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
Telescope captures information about lonely Jupiter-like gas giant
May 13, 2026
Science outlets highlight a University of Cincinnati student's collaborative discoveries about an exoplanet 901 light years away.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.